Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keeping Track: US FDA Expands Indications For Roche Tecentriq, Lucentis, Approves Second Infliximab Biosimilar

Executive Summary

The latest drug development news and highlights from our FDA Performance Tracker.

Advertisement

Related Content

Keeping Track Of CRLs: US FDA Again Faults Bausch + Lomb Manufacturing
Keeping Track: Clarus, Agile and Sunovion Look To Bounce Back From CRLs; FDA To Review Rituximab Biosimilar
Samsung’s Renflexis: Second US Biosimilar To Janssen’s Remicade, With A Few Firsts
Keeping Track: US FDA Approvals Binge Continues With Dupixent, Ocrevus And Zejula; Two CAR-T Are Under Review
BLA Accepted: Novartis Inches Ahead In CAR-T Race With Kite
US FDA First's RMAT Designation: Humacyte Got A 'Quick Response'
Tech Transfer Roundup: Aduro Hopes Stanford Algorithm Will Optimize Its IO Candidates
Pressure On Tecentriq: Bladder Cancer Heats Up With Opdivo Approval, Keytruda Filing
Atezolizumab At Last: Roche Makes Its Immuno-Oncology Debut
Keeping Track: Gazyva, Afinitor Get New Indications; PTC's Translarna Gets Refuse To File

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS120470

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel